EMA Application withdrawn: Vekacia (ciclosporin) — Novagali Pharma S.A.

View source ↗

Summary

The EMA withdrew the application for Vekacia (ciclosporin) by Novagali Pharma S.A. for allergic conjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Vekacia (ciclosporin)

Snippet

Status: Application withdrawn. Therapeutic area: Conjunctivitis, Allergic. MAH: Novagali Pharma S.A.. Decision date: 31/12/2009. Orphan medicine